Agree Orioles. Though I think the deal will be on a PH2b NASH to get the higher dosing tested before a PH3 (& eventual market launch ) Anyway concur. Do you think (on this pharma deal) that it's unreasonable to expect a USD$350mio market cap before the close of 2018?
Add to My Watchlist
What is My Watchlist?
